IZOZF - Izotropic Announces Upgrade to OTCQB Venture Market
(TheNewswire)
VANCOUVER, BC - TheNewswire - February 3, 2021 - Izotropic Corporation (“ Izotropic ” or the “ Company ”) (C NSX : IZO. CN ) (OTC: IZOZF )(FSE: 1R3 ), a company commercializing true 3D, dedicated breast CTimaging technology for the earlier detection, diagnosis and treatmentof breast cancers, is pleased to announce it has upgraded its U.S.listing to the OTCQB Venture Market (OTCQB),effective at the opening of trading today, February 3, 2021.
“Upgrading to the OTCQB is a milestone for theCompany that shows our commitment to building our shareholder base,”said Robert Thast, CEO of Izotropic. “We believe the upgrade willenhance trading liquidity through increased market visibility andawareness in the U.S. investment community.”
The upgrade announcement comes one day after the World Health Organization announced that breast cancer has nowsurpassed lung cancer as the most common form of the disease,demonstrating the need for earlier detection and improved breastimaging technologies.
ON BEHALF OF THE BOARD
For investor relations inquiries contact:
Dan Sammartino
Phone: 1-778-962-0234
Email: IR@izocorp.com
For general inquiries contact:
Izotropic Corporation
Phone: 1-833-IZOCORP
Email: info@izocorp.com
About Izotropic Corporation
Izotropic Corporation is commercializing dedicatedbreast CT imaging technology for the earlier detection, diagnosis andtreatment of breast cancers. Extensive preliminary studies have foundthat breast CT may be able to routinely detect small breast tumors inthe 3-5 mm size range. The median size of breast cancer found usingmammography is approximately 11 mm. Routine detection of 3 mm lesionswould result in 1.5 year earlier detection over mammography.
The initial indication for use for breast CT as a diagnostic devicehas been confirmed. Forthcoming business objectives includeidentifying additional indications for use, development ofaccessories, and additional products, all aimed at making breast CT anindispensable tool for improving the outcomes of breast cancer.
Additional infor mationabout Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com
Forward Looking Statements
This document may contain statements that are“Forward-Looking Statements,” which are based upon the currentestimates, assumptions, projections and expectations of thecompany’s management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify such information and statements byusing words such as “anticipate,” “believe,” “envision,”“estimate,” “expect,” “intend,” “may,” “plan,”“predict,” “project,” “target,” “potential,”“will,” “would,” “could,” “should,” “continue,”“contemplate” and other similar expressions and derivationsthereof in connection with any discussion of future events, trends orprospects or future operating or financial performance, although notall forward-looking statements contain these identifying words. Thesestatements are not guarantees of performance and involve risks anduncertainties that are difficult to control or predict, and as suchthey may cause future results of the company’s activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the companynor its shareholders, officers and consultants, shall be liable forany action and the results of any action taken by any person based onthe information contained herein, including without limitation thepurchase or sale of company securities. Nothing in this documentshould be deemed to be medical or other advice of any kind.
Copyright (c) 2021 TheNewswire - All rights reserved.